efpeglenatide
AssetAlso HM-11260C, SAR-439977, Epeg, Efe
Activates GLP-1 receptors to reduce appetite and enhance glucose-dependent insulin secretion.
- Stage
- Approved
- Modality
- Peptide
- Target
- Insulin/IGF-1 signalling
- 2
- Indications
- 0
- Trials
- 1
- Developer
Indications
2Obesity
Approved, hitnews.co.kr, 12 Oct 2026
Overweight
Approved, hitnews.co.kr, 9 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Evidence for its targets3
- Competitors12
- Aging relevance1
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.